Physician profile
Keith Sueling
NPI 1730108846
$590.22
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $215 · 2021: $217.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $125.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $89.34 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $83.94 | 2019-2021 | |
| Esperion Therapeutics, INC. | $73.79 | 2020-2021 | |
| Amarin Pharma, INC. | $59.47 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $46.13 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $36.66 | 2020-2021 | |
| Novo Nordisk INC | $28.42 | 2021 | |
| Boston Scientific Corporation | $22.18 | 2020 | |
| Amgen INC. | $12.80 | 2021 | |
| Gilead Sciences, INC. | $12.49 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Sueling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.